|Over a week ago|
Rallybio reports Q2 EPS ($2.80), two estimates ($4.30) » 07:1809/0909/09/21
"Since our founding…
"Since our founding in 2018, Rallybio has made consistent progress towards achieving our mission to truly transform the lives of patients with severe and rare diseases. With a tremendous team, we have now built a diversified portfolio of five programs, and we continue to work expeditiously to advance our pipeline," said Martin Mackay, CEO of Rallybio. "Following the closing of our initial public offering in early August, we are operating from a position of financial strength, and we are poised to build on this momentum in the months ahead, with additional Phase 1/2 data for RLYB211 expected before year end, and the initiation of Phase 1 studies of RLYB212 and RLYB116 both planned for the first quarter of 2022."
Rallybio initiated with an Outperform at Evercore ISI » 08:2908/2308/23/21
Evercore ISI analyst Josh…
Evercore ISI analyst Josh Schimmer initiated coverage of Rallybio with an Outperform rating and $40 price target. The analyst also added the stock to Evercore's SMID "Core" ideas list. Rallybio is one of the most compelling risk/rewards in biotech, Schimmer tells investors in a research note. He says the company's antibody therapies for fetal and neonatal alloimmune thrombocytopenia "essentially rewrite the RhoGam script" and that there's more to the story that could justify upside to the current valuation independent of FNAIT.
Rallybio initiated with an Outperform at Cowen » 08:1508/2308/23/21
As reported previously,…
As reported previously, Cowen analyst Ritu Baral initiated coverage of Rallybio with an Outperform rating. The analyst said it is a clinical stage co developing therapeutics for rare diseases in maternal fetal health hematology immuno-inflammation and metabolic disorders. Baral said Earlier stage complement programs also have major promise.
Rallybio initiated with a Buy at Jefferies » 07:3408/2308/23/21
Jefferies analyst Eun…
Jefferies analyst Eun Yang initiated coverage of Rallybio with a Buy rating and $20 price target. Lead asset, RLYB212 for FNAIT prevention, is set to enter Phase 1/1b in 1Q22 with Phase 1b data in mid-2022 and if successful, Yang forecasts U.S./Europe combined sales of ~$1B in ~2032, the analyst tells investors in a research note. Preclinical programs including the C5 and ENPP1 inhibitor programs, provide potential additional upside if successful, Yang adds.
Rallybio initiated with a Buy at Jefferies » 06:1008/2308/23/21
Jefferies analyst Eun…
Jefferies analyst Eun Yang initiated coverage of Rallybio with a Buy rating and $20 price target.
Rallybio initiated with an Outperform at Cowen » 06:0908/2308/23/21
Cowen analyst Ritu Baral…
Cowen analyst Ritu Baral initiated coverage of Rallybio with an Outperform rating.
|Over a month ago|
Opening Day: Sportradar files for IPO after SPAC talks break off » 08:2708/2108/21/21
ARBK, ARBKF, PRCT, SRAD, QNIU, CMSL, SPRK, SCAN, AUTH, BLK, SPG, MS, GS, BCS, BAC, MXCT, RXST, TNYA, RANI, NUVL, ICVX, RSKD, OMGA, IMRX, INAB, HOOD, RLYB, ABVC
In a quiet week for IPOs,…
Rallybio director Hopfner buys $7.5M in company shares » 18:0508/0408/04/21
Rallybio director Robert…
Rallybio director Robert Hopfner disclosed in a regulatory filing that he had purchased 576,923 shares of company stock at $13.00 per share on August 2 for a total transaction amount of $7,499,999.
Opening Day: Robinhood shares fall after IPO » 08:5307/3107/31/21
MXCT, RXST, TNYA, RANI, OMGA, IMRX, INAB, DOLE, HOOD, NUVL, ICVX, RSKD, COOK, RLYB, DUOL, MLNK, PWSC, CADL, SNTG, RNAZ, AGRI, MITQ, IINN, UNCY, SPRK, QNIU, CMSL, SCAN, AUTH, MS, GS, BCS, BAC, BLK, SPG
Shares of Robinhood…
Rallybio Holdings LLC trading resumes 09:4207/3007/30/21